Gastritis Clinical Trial
Official title:
Retrospective Study on Endoscopic Findings of Gastritis in Children Attending GIT Endoscopic Unit of Assiut University Children Hospital (AUCH) (15 Years)
Gastritis defines any (histologically confirmed) inflammation of the gastric mucosa
Gastritis is a very common disease in children. The main presentation of children with
gastritis is recurrent abdominal pain and dyspepsia or vomiting. Young children may have
hematemesis or melena as presentation. Drug induced or food related gastritis presents
usually with acute symptoms but Helicobacter pylori gastritis have mainly recurrent abdominal
pain and dyspeptic symptoms. Other presentations include diarrhea, constipation, flatulence,
bloating, fatigue, low energy level, weight loss, muscle loss, bad breath etc.
The main causes of gastritis are infections, inflammation and other disorders affect the
gastric mucosa in pediatric patients. Helicobacter pylori infection is the most common cause
of gastritis in children which is also responsible for the majority of duodenal ulcers.
Acute erosive gastritis is most commonly the result of metabolic stress or drug or corrosive
injury.
Other major causes of gastritis include celiac disease, allergic disorders, and Crohn's
disease .Medication as NSAIDs, uremia, ischemia, shock, radiation, sepsis, trauma, severe
burns and surgery.
Endoscopic pictures in acute gastritis may be in the form of:
- Multiple round-shaped severe erosions with a diameter of several millimeters.
- Mucosal edema, hyperemia.
- Peptic ulcer While in chronic gastritis is variable. Affects the antrum in the beginning
and advances to the proximal in time .
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02353039 -
Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis
|
Phase 2 | |
| Recruiting |
NCT05545397 -
Sedation Level on Machine Learning With Electroencephalogram in Painless Gastroenteroscopy Patients
|
||
| Not yet recruiting |
NCT05510388 -
HFNO Reduces Hypoxia During Sedated Gastroscopy or Colonoscopy in High Risk Patients
|
N/A | |
| Completed |
NCT02724280 -
Linked Color Imaging to Differentiate H. Pylori Associated Gastritis and Gastric Atrophy
|
N/A | |
| Not yet recruiting |
NCT02961296 -
Helicobacter Pylori Antibiotic Susceptibility Testing of Korea
|
N/A | |
| Completed |
NCT02385045 -
i-Scan for the Detection of Helicobacter Pylori
|
N/A | |
| Completed |
NCT00212225 -
Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori)
|
N/A | |
| Completed |
NCT04672018 -
Efficacy and Safety of Houtou Jianweiling Tablet in the Treatment of Chronic Non-Atrophic Gastritis
|
Phase 2 | |
| Not yet recruiting |
NCT05072938 -
Phase IV Clinical Trial to Compare the Efficacy and Safety of Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis
|
Phase 4 | |
| Completed |
NCT02597517 -
New Technology to Differentiate Normal Gastric Mucosa From Helicobacter Pylori Associated Gastritis and Gastric Atrophy
|
N/A | |
| Completed |
NCT02296021 -
Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy
|
Phase 4 | |
| Completed |
NCT01576289 -
Analysis of Biopsies From the Upper Gastrointestinal Tract
|
N/A | |
| Active, not recruiting |
NCT03509831 -
[KJ-INT-002] BE Study
|
Phase 1 | |
| Terminated |
NCT05579444 -
Systems Biology of Gastrointestinal and Related Diseases
|
||
| Suspended |
NCT04306939 -
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
|
||
| Completed |
NCT05237115 -
Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy
|
Phase 4 | |
| Completed |
NCT02393430 -
Clinical Effect of Rebamipide on Chronic Gastritis
|
Phase 4 | |
| Completed |
NCT00579410 -
Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule
|
N/A | |
| Completed |
NCT00267475 -
Data Bank for Eosinophilic Disorders
|
N/A | |
| Completed |
NCT05155072 -
Clinical Trial to Evaluate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of DW1903
|
Phase 1 |